Addenbrooke's Hospital

Running trials

• Not yet recruiting

  A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

  NCT07919405· Phase 3· Source

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· Source

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Source

• Recruiting

  A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

  NCT07158242· Phase 3· Source

• Recruiting

  A Gaucher Disease Gene Therapy Trial With FLT201

  NCT07223944· Phase 3· Source

• Recruiting

  DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

  NCT07440290· Phase 2/3· Source

• Recruiting

  Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells

  NCT07610538· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  NCT07293351· Phase 1/2· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

  NCT07463183· Phase 2· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Source

• Not yet recruiting

  DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

  NCT07483801· Phase 4· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Source

• Recruiting

  Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

  NCT07053800· Phase 2· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Source

• Recruiting

  A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

  NCT07287982· Phase 2· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Source

• Recruiting

  DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

  NCT05770544· Phase 2/3· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Source

• Recruiting

  Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

  NCT07139743· Phase 1· Source

• Recruiting

  Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer

  NCT06976892· Phase 1· Source

• Recruiting

  A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

  NCT06863272· Phase 1/2· Source

• Recruiting

  Bladder EpiCheck European Haematuria Study

  NCT06818136· Source

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

  NCT06977581· Phase 2· Source

• Recruiting

  A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  NCT06925737· Phase 3· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Source

• Recruiting

  A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

  NCT06827236· Phase 1/2· Source

• Recruiting

  ARMSTRONG - Air entRainMent vS sTandard tReatment in nOn-expandable luNG

  NCT06959719· Source

• Recruiting

  Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· Phase 3· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  NCT06615479· Phase 3· Source

• Active, not recruiting

  Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

  NCT05093231· Phase 2· Source

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Source

• Active, not recruiting

  A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

  NCT06780449· Phase 3· Source

• Recruiting

  DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

  NCT06988475· Phase 2/3· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06497556· Phase 3· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Source

• Active, not recruiting

  A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

  NCT06540391· Phase 1· Source

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· Source

• Active, not recruiting

  A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

  NCT06388733· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· Phase 3· Source

• Recruiting

  A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

  NCT06439277· Phase 3· Source

• Recruiting

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· Phase 3· Source

• Recruiting

  Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study

  NCT06427694· Source

• Active, not recruiting

  Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

  NCT06353386· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers12 recruiting
• Lung cancer10 recruiting
• Prostate cancer9 recruiting
• Colorectal cancer6 recruiting
• Melanoma6 recruiting
• Multiple myeloma6 recruiting
• Ovarian cancer6 recruiting
• Pancreatic cancer5 recruiting
• Bladder cancer4 recruiting
• High blood pressure4 recruiting
• Kidney cancer4 recruiting
• Liver and biliary tract cancer4 recruiting
• Gastric and esophageal cancer3 recruiting
• Head and neck cancer3 recruiting
• Sarcoma3 recruiting
• Stroke3 recruiting
• Thyroid cancer3 recruiting
• Cervical cancer2 recruiting
• Coronary artery disease2 recruiting
• Crohn's disease2 recruiting
• Endometrial cancer2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Lupus (SLE)2 recruiting
• Mesothelioma2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Neuroblastoma2 recruiting
• Neuroendocrine tumours2 recruiting
• Obesity2 recruiting
• Type 1 diabetes2 recruiting
• Type 2 diabetes2 recruiting
• Ulcerative colitis2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• ANCA-associated vasculitis1 recruiting
• Asthma1 recruiting
• Atrial fibrillation1 recruiting
• Gaucher disease1 recruiting
• Haemophilia1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple sclerosis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Pompe disease1 recruiting
• Sickle cell disease1 recruiting
• Spinal muscular atrophy1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· Source

• Completed

  A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

  NCT06582264· Phase 1· Source

• Completed

  A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

  NCT06388187· Phase 3· Source

• Terminated

  Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2

  NCT06264479· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Source

• Completed

  A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

  NCT05936151· Phase 2· Source

• Completed

  Closing the Loop in People with Type 1 Diabetes

  NCT05653050· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Source

• Completed

  A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

  NCT05659264· Phase 1· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

  NCT05267106· Phase 2· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Source

• Completed

  Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

  NCT04966741· Phase 3· Source

• Completed

  CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy

  NCT05131828· Phase 2· Source

• Completed

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· Phase 3· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Source

• Completed

  Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

  NCT04776148· Phase 3· Source

• Completed

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· Phase 3· Source

• Terminated

  IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

  NCT04524949· Phase 2· Source

• Terminated

  Abiraterone Acetate in Combination With Tildrakizumab

  NCT04458311· Phase 1/2· Source

• Completed

  Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

  NCT04472429· Phase 3· Source

• Completed

  AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

  NCT04006405· Source

• Completed

  Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

  NCT04046224· Phase 1/2· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Source

• Completed

  Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

  NCT04173533· Phase 3· Source

• Completed

  BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

  NCT03762018· Phase 3· Source

• Completed

  Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

  NCT03614234· Phase 3· Source

• Completed

  Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

  NCT03566017· Phase 3· Source

• Completed

  Multiple Sclerosis-Simvastatin Trial 2

  NCT03387670· Phase 3· Source

• Completed

  Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

  NCT02947347· Phase 3· Source

• Completed

  Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis

  NCT02923206· Source

• Completed

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· Phase 3· Source

• Completed

  Gene Therapy Study in Severe Haemophilia A Patients (270-201)

  NCT02576795· Phase 1/2· Source

• Completed

  Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

  NCT02360579· Phase 2· Source

• Completed

  Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

  NCT02369731· Source

• Completed

  Stereotactic Radiotherapy for Wet AMD (STAR)

  NCT02243878· Phase 3· Source

• Completed

  Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers

  NCT01597219· Phase 2· Source

• Completed

  Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours

  NCT01726374· Phase 3· Source

Trial sites

• Addenbrooke's Hospital126 trials
• Addenbrooke's Hospital Cambridge8 trials
• Addenbrooke's Hospital - Cambridge Dialysis Centre1 trial
• Addenbrooke's Hospital, Central Pharmacy, Level 11 trial
• Addenbrooke's Hospital - Dept of Oncology1 trial
• Addenbrooke's Hospital - Haemophilia and Thrombophilia1 trial
• Addenbrooke's Hospital, Hemophilia and Thrombophilia Center1 trial
• Addenbrooke's Hospital /ID# 2230971 trial
• Addenbrooke's Hospital in Cambridge (Site 0600)1 trial
• Addenbrooke's Hospital - Oncology1 trial
• Addenbrooke's Hospital (Site 0747)1 trial
• Addenbrooke's Hospital (Site 0915)1 trial
• Addenbrooke's Hospital (Site 1004)1 trial
• Addenbrooke's Hospital (Site 1309)1 trial
• Addenbrooke's Hospital (Site 1407)1 trial
• Addenbrooke's Hospital (Site 1426)1 trial
• Addenbrooke's Hospital (Site 1525)1 trial
• Addenbrooke's Hospital (Site 1605)1 trial
• Addenbrooke's Hospital (Site 1610)1 trial
• Addenbrooke's Hospital (Site 1800)1 trial
• Addenbrooke's Hospital (Site 1902)1 trial
• Addenbrooke's Hospital (Site 2005)1 trial
• Addenbrooke's Hospital (Site 2200)1 trial
• Addenbrooke's Hospital (Site 2203)1 trial
• Addenbrooke's Hospital (Site 2400)1 trial
• Addenbrooke's Hospital (Site 2808)1 trial
• Addenbrooke's Hospital (Site 3217)1 trial
• Addenbrooke's Hospital (Site 3303)1 trial
• Addenbrooke's Hospital, Wellcome Trust-MRC Institute of Metabolic Science1 trial
• Cambridge Clinical Trials Unit, Addenbrooke's Hospital1 trial
• Cambridge University - Addenbrooke's Hospital3 trials

Conditions

Diseases this institution publishes on or runs trials for.

• ANCA-associated vasculitis7 works · 1 trials